Improving the return on R&D investments


The technology consists in a vaccine which can be administrated through the mucosa (oral and/or intranasal) for the treatment and control of PCV2 associated diseases. Additionally, this vaccine includes a microencapsulated antigen, which permits to deliver an efficient and harmless immunization and also controlled delivery to the therapeutic target.
This innovation also has the potential for the development of mucosal vaccines, to control and treat certain types of diseases generated by infectious agents such as virus, bacteria and parasites, which use the heparan sulphate as cell receptor.


  • Animal well-being: It avoids adverse reactions in the injection site, which is detrimental for product quality as well as it avoids the pain and stress for the animals.
  • Easy handling and application: Its administration is easier than the injectables, since it does not require specialized technical staff, and avoids the workplace hazards associated with the use of hypodermic needles.
  • Efficient oral administration: It allows to control the delivery of active compounds, without degradation of the active principle while it is carried through the gastrointestinal tract.
  • An option for massive immunization: It can be efficiently scaled up to be used by breeders as a main immunization program, or as booster dose.
  • Inexpensive: : Vaccine production is simple and inexpensive. This is because reagents and its preparation are simple and economic. Additionally, the preparation method used generates high yields.


The solution applies particularly to the swine industry but also, it has potential applications in livestock industry, which includes: swine, equestrian, cattle, sheep and goat.


  • Oral vaccine
  • Porcine circovirus type 2
  • Massive immunization
  • Heparan sulphate
  • Porcine circovirosis

More information


Nataly Pizarro · Project Manager

Nataly Pizarro


Knowledge Innovation Market - KIM